Antibody–drug conjugates in non-Hodgkin lymphoma
Mené sur 95 patients atteints d'un lymphome non hodgkinien à cellules B ou d'une leucémie lymphocytaire chronique, cet essai de phase I évalue la dose maximale tolérée, la toxicité et l'efficacité, du point de vue du taux de réponse objective, du polatuzumab vedotin en combinaison avec le rituximab
Although the outcome of patients with non-Hodgkin lymphoma has improved over the years, patients who relapse after rituximab-based treatment often remain resistant to salvage therapy. As first-line therapy, immunochemotherapy such as rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisolone (R-CHOP) remains unsatisfactory in patients with high-risk disease. More intensive approaches, including upfront high-dose chemotherapy and autologous stem-cell transplantation, have not been shown to be beneficial and might not be tolerated by older patients.
The Lancet Oncology , commentaire, 2014